DANIEL E. LEVY, PhD, is the Director of Synthetic Chemistry at Intradigm Corporation, pursuing delivery vehicles for siRNA therapeutics. He previously worked at Glycomed Inc., where he pursued the design and synthesis of novel glycomimetics for the treatment of cancer and inflammatory disorders; COR Therapeutics, where he pursued carbocyclic AMP analogs as inhibitors of type V adenylyl cyclase; and at Scios, Inc., where he pursued novel kinase inhibitors. Dr. Levy coauthored a book entitled The Chemistry of C-Glycosides and later collaborated with Dr. Péter Fügedi in the development and presentation of short courses entitled "Modern Synthetic Carbohydrate Chemistry" and "The Organic Chemistry of Sugars" offered by the American Chemical Society Continuing Education Department. Most recently, Dr. Levy coedited with Dr. Fügedi the book The Organic Chemistry of Sugars, based on the short course of the same name. Dr. Levy received his BS in chemistry from the University of California, Berkeley, and his PhD in organic chemistry from the Massachusetts Institute of Technology.